Endoscopic Sleeve Gastroplasty Efficacy (ENvISaGE) Study: Characteristics of ESG and matched LSG patients from the first Queensland ESG clinic
Marshall, Skye; Cohen, Felicity; Rich, Graeme; Soni, Asha; Isenring, Elisabeth

Published in:
Obesity Surgery

DOI:
10.1007/s11695-019-04101-1

Published: 01/09/2019

Document Version:
Peer reviewed version

Link to publication in Bond University research repository.

Recommended citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.
EndoscopIc Sleeve Gastroplasty (ENvISaGE) Study
Characteristics of ESG and matched LSG patients from the first Queensland ESG Clinic

An observational prospective cohort study 2018-2020

Presenter: Dr Skye Marshall
BNutr&Diet, APD, PhD

skye_marshall@bond.edu.au, @DrSkyeMarshall
Background

The Endoscopic Sleeve Gastroplasty (ESG) is new to Australia.

It’s minimally invasive procedure is designed to mimic the Laparoscopic Sleeve Gastropalst (LSG).

The ENvISaGE Study will observe procedural safety, change in body composition, comorbidities, and quality of life in adults undergoing the ESG and LSG.

Objectives and methods

To compare pre-op characteristics of ESG and matched LSG patients to guide interpretation of post-op outcomes.

Participants were matched for BMI and gender.

Body composition by DXA, quality of life by Impact of Weight on Quality of Life Tool-Lite, GI symptoms by Gastrointestinal Symptom Rating Scale. Bloods, medical status, adverse events by medical record.

ESG  
\[ \text{n=}18 \text{ recruited} \]

Matched for:
- BMI: mean 35.7 (4.7) kg/m²
- Sex: 83% female
- Age: mean 41.0 (9.7) years

LSG  
\[ \text{n=}18 \text{ recruited} \]
LSG had higher prevalence of anxiety and/or depression (56% vs 22%, p<0.05)

ESG had higher systolic blood pressure (129 vs 120 mmHG, p<0.05)

LSG had higher HbA1c (34 vs 30 mol/mmol, p<0.01)

LSG had lower high-density lipoprotein (1.3 vs 1.6 mmol/L, p<0.05)

LSG had worse weight-related self-esteem (11% vs 29%, p<0.05)

No difference in:
- Pre-op adverse events (0%)
- GORD (35%), Sleep apnoea (31%), Arthritis (61%), Backpain (64%), PCOS (8%)
- T2DM (0%), Fasting blood glucose (5.0mmol/L)
- HTN (30%), diastolic blood pressure (82 mmHg),
- Dyslipidaemia (9%), T. Chol (5.3mmol/L), LDL (3.3mmol/L), HDL (1.4mmol/L), TG (1.5mmol/L)
- NAFLD (5%), ALT (33.3U/L), AST (25.4U/L)
- Gastrointestinal symptoms including reflux, constipation, diarrhoea, indigestion, GI pain (35/105 points)
- Weight-related physical function, sexual life, public distress, work, or total quality of life (51%)
- Android to gynoid fat mass ratio (0.57), fat mass (47.3%), lean mass (49%)